This article will be permanently flagged as inappropriate and made unaccessible to everyone. Are you certain this article is inappropriate? Excessive Violence Sexual Content Political / Social
Email Address:
Article Id: WHEBN0011584979 Reproduction Date:
InChI=1S/C19H29N5O2/c1-19(2)14-16(25)24(17(26)15-19)9-4-3-8-22-10-12-23(13-11-22)18-20-6-5-7-21-18/h5-7H,3-4,8-15H2,1-2H3 Y Key:QOIGKGMMAGJZNZ-UHFFFAOYSA-N Y
Gepirone (Ariza, Variza; BMY-13,805, ORG-13,011) is an antidepressant and anxiolytic of the azapirone class. Like other azapirones, it acts as a selective partial agonist of the 5-HT1A receptor. Gepirone was under development in the U.S. in an extended release form, but despite completing phase III clinical trials, it failed to pass the drug approval process. As a result, gepirone, despite already having brand names picked out, did not manage to reach the pharmaceutical market.
Gepirone was originally developed by Bristol-Myers Squibb, but was out-licensed to Fabre-Kramer in 1993. The U.S. Food and Drug Administration (FDA) rejected approval for gepirone in 2004. It was submitted for the preregistration (NDA) phase again in May 2007 after adding additional information from clinical trials as the FDA required in 2004. However, in 2007 it once again failed to convince the FDA of its qualities for
Diamond, Graphite, Solar system, Coal, /anolanthanide Chemistry
Oxygen, Argon, Hydrogen, Helium, Gold
Nitrogen, Hydrogen, Helium, Sulfur, Fluorine
5-Carboxamidotryptamine, 5-Methoxytryptamine, Lysergic acid diethylamide, Metitepine, Methysergide
Metitepine, 5-Carboxamidotryptamine, 5-Methoxytryptamine, Lysergic acid diethylamide, Bromocriptine
Metitepine, 5-Carboxamidotryptamine, 5-Methoxytryptamine, Lysergic acid diethylamide, Ziprasidone